The 28 references in paper M. Nuijten ., A. Rudakova ., T. Marshall ., М. Нюйтен ., А. Рудакова В., Т. Маршалл . (2014) “ЭФФЕКТИВНОСТЬ ЗАТРАТ НА ПАРИКАЛЬЦИТОЛ И КОМБИНАЦИЮ ЦИНАКАЛЬЦЕТА И НЕСЕЛЕКТИВНЫХ ПРЕПАРАТОВ ВИТАМИНА D ПРИ ХРОНИЧЕСКОЙ БОЛЕЗНИ ПОЧЕК VД СТАДИИ В РОССИЙСКОЙ ФЕДЕРАЦИИ // HEALTH ECONOMIC EVALUATION OF PARICALCITOL AND COMBINATION OF CINACALCET WITH NON-SELECTIVE VITAMIN D IN PATIENTS WITH CHRONIC KIDNEY DISEASE 5D STAGE IN RUSSIAN FEDERA-TION” / spz:neicon:nefr:y:2014:i:6:p:64-70

1
Levey A.S., Eckardt K.U., Tsukamoto Y., et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO) // Kidney Int. 2005; 67(6): 2089-100.
(check this in PDF content)
2
K/DOQI guidelines,www.kidney.org/professionals/kdoqi/ guidelines_bone/Guide8B.htm, accessed Feb 2nd, 2005
(check this in PDF content)
3
Alebiosu C.O., Ayodele O.E. The global burden of chronic kidney disease and the way forward // Ethn Dis. 2005;15(3): 418-23.
(check this in PDF content)
4
Dirks J.H., de Zeeuw D., Agarwal S.K., et al. International Society of Nephrology Com-mission for the Global Advancement of Nephrology Study Group 2004. Prevention of chronic kidney and vascular disease: toward global health equity--the Bellagio 2004 Dec-laration // Kidney Int. Suppl. 2005; 98: S1-6.
(check this in PDF content)
5
Stehman-Breen C.O., Sherrard D.J., Alem A.M. et al. Risk factors for hip fracture among patients with end-stage renal disease // Kidney Int. 2000; 58: 2200–2205.
(check this in PDF content)
6
Mazhar A.R., Johnson R.J., Gillen D. et al. Risk factors and mortality associated with cal-ciphylaxis in end-stage renal disease // Kidney Int. 2001; 60: 324–332.
(check this in PDF content)
7
Ahmed S., O’Neill K.D., Hood A.F. et al. Calciphylaxis is associated with hyperphosphatemia and increased osteopontin expression by vascular smooth muscle cells // Am. J. Kidney Dis. 2001; 37: 1267–1276.
(check this in PDF content)
8
Ganesh S.K., Stack A.G., Levin N.W. et al. Association of ele-vated serum PO4, Ca_PO4 product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients // J. Am. Soc. Nephrol. 2001; 12: 2131–2138.
(check this in PDF content)
9
Smirnov A.V. et al. National guidelines on CKD: general statements, definition, diagnos-tic, screening, approaches to prophylaxis and treatment // Nefrologiya. St-Petersburg, 2012.
(check this in PDF content)
10
Goodman W.G. The consequences of uncontrolled secondary hyperparathyroidism and its treatment in chronic kidney disease // Semin. Dial. 2004; 17 (3): 209-16.
(check this in PDF content)
11
Block G.A., Port F.K. Re-evaluation of risks associated with hyperphosphataemia and hy-perparathyroidism in dialysis patients: recommendations for a change in management // Am. J. Kidney Dis. 2000; 35: 1226-1237.
(check this in PDF content)
12
Goodman W.G., Goldin J., Kuizon B.D., et al. Coronary artery calcification in young adults with end-stage renal disease who are undergoing dialysis // N. Engl. J. Med. 2000; 342: 1478-83.
(check this in PDF content)
13
Block G.A., Hulbert-Shearon T.E., Levin N.W., et al. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic HD patients: a national study // Am. J. Kidney Dis. 1998; 31: 607-617.
(check this in PDF content)
14
National recommendations on CKD-MBD. RDS working group // Nefrologija I Dializ 2011; 13 (1): 33-51.
(check this in PDF content)
15
Zandi-Nejad K., Brenner B.M. Strategies to retard the progression of chronic kidney dis-ease // Med. Clin. North Am. 2005; 89 (3): 489-509.
(check this in PDF content)
16
Nuijten M., Andress D.L., Marx S.E., Curry A.S., Sterz R. Cost Effectiveness of Parical-citol versus a non-selective vitamin D receptor activator for secondary hyperparathyroid-ism in the UK: a chronic kidney disease markov model // Clin. Drug Investig. 2010; 30 (8): 545-57.
(check this in PDF content)
17
Бикбов Б.Т., Томилина Н.А. Состояние заместительной терапии больных с хрониче-ской почечной недостаточностью в Российской Федерации в 1998-2007 гг. (Аналитический отчет по данным Российского регистра заместительной почечной терапии // Нефрология и диализ 2009; 11 (3): 144233 [Bikbov B.T., Tomilina N.A. Sostoianie zamestitel`noi` terapii bol`ny`kh s khronicheskoi` pochechnoi` nedostatochnost`iu v Rossii`skoi` Federatcii v 1998-2007 gg. (Analiticheskii` otchet po danny`m Rossii`skogo registra zamestitel`noi` pochechnoi` terapii // Nefrologiia i dializ 2009; 11 (3): 144-233]
(check this in PDF content)
18
Dobrez D., Mathes A., Amdahl M. et al. Paricalcitol-treated patients experience improved hospitalization outcomes compared with calcitriol-treated patients in real-world clinical settings // Nephrol. Dial. Transplant. 2004; 5: 1174-1181.
(check this in PDF content)
19
Teng M., Wolf M., Lowrie E., et al. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy // N. Engl. J. Med. 2003; 349: 446-56.
(check this in PDF content)
20
Cunningham J., Danese M.D., Olson K.A., Klassen P., Chertow G.M. Effects of the cal-cimimetic cinacalcet HCI on cardiovascular disease, fracture, and health related quality of life in secondary hyperparathyroidism // Kidney Int. 2005;68: 1793–800.
(check this in PDF content)
21
Garside R., Pitt M., Anderson R., et al. The effectiveness and cost-effectiveness of ci-nacalcet for secondary hyperparathyroidism in end-stage renal disease patients on dialysis: a systematic review and economic evaluation // Health Technology Assessment 2007; 11 (18).
(check this in PDF content)
22
Ketteler M., Martin K.J., Wolf M., et al. Paricalcitol versus cinacalcet plus low-dose vi-tamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: results of the IMPACT SHPT study // Nephrol Dial Transplant. 2012 Mar 19. [Epub ahead of print].
(check this in PDF content)
23
Roderick P., Nicholson T., Armitage A., et al. An evaluation of the costs, effectiveness and quality of renal replacement therapy provision in renal satellite units in England and Wales // Health Technol Assess. 2005; 9 (24): 1-178.
(check this in PDF content)
24
Приложения к Генеральному тарифному соглашению по тарифам на медицинскую помощь (медицин¬ские услуги) и условиям оплаты медицинской помощи, оказывае-мой в рамках действующей Территори¬альной программы обязательного медицин-ского страхования граждан Российской Федерации в Санкт-Петербурге на 2012 г. (www.spboms.ru) [Prilozheniia k General`nomu tarifnomu soglasheniiu po tarifam na meditcinskuiu pomoshch` (meditcinskie uslugi) i usloviiam oplaty` meditcinskoi` pomoshchi, okazy`vae-moi` v ramkakh dei`stvuiushchei` Territori¬al`noi` programmy` obiazatel`nogo meditcin-skogo strahovaniia grazhdan Rossii`skoi` Federatcii v Sankt-Peterburge na 2012 g. (www.spboms.ru)]
(check this in PDF content)
25
Nuijten M. Data management in modelling studies: the selection of data sources // Phar-macoEconomics 1998; 3: 305-316.
(check this in PDF content)
26
Llach F., Velasquez-Forero F.. Secondary Hyperparathyroidism in chronic renal failure; pathogenic and clinical aspects // Am. J. Kidney Dis. 2001; 38 (5): Suppl 5 S20-S33.
(check this in PDF content)
27
Goodman W.G. The consequences of uncontrolled secondary hyperparathyroidism and its treatment in chronic kidney disease // Semin. Dial. 2004 May-Jun;17(3):209-16.
(check this in PDF content)
28
Urena Torres P. Clinical experience with cinacalcet HCl // Nephrol. Dial. Transplant. 2004 Aug;19 Suppl 5: V27-33. Поступила в редакцию: 15.05.2014 г. Принята в печать: 02.09.2014 г.
(check this in PDF content)